Skip to main content
Clinical Trials/NCT04402372
NCT04402372
Unknown
Not Applicable

Comparative Clinical Efficacy of Novel Bidirectional Peripheral Artery Cannula in Minimally Invasive Aortic Valve Surgery

Ankara City Hospital Bilkent1 site in 1 country60 target enrollmentMarch 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Efficacy and Safety of Novel Bidirectional Cannula
Sponsor
Ankara City Hospital Bilkent
Enrollment
60
Locations
1
Primary Endpoint
Vascular complications
Last Updated
5 years ago

Overview

Brief Summary

The aim of this study is to evaluate the safety and efficacy of the novel bidirectional cannula (BiflowTM, LivaNova, Italy) with specific design to ensure stable distal perfusion compared to conventional cannula with downstream line in patients undergoing femoral arterial cannulation for cardiopulmonary bypass during minimally invasive surgery

Detailed Description

The femoral artery is a common site for peripheral cannulation in patients requiring cardiopulmonary bypass (CPB) for minimally invasive cardiac surgical procedures (MICS), redo cardiac surgical procedures, and procedures involving the thoracic aorta Limb ischemia is the most common acute and late vascular complication and has been reported in 10% to 70% of patients Traditional methods to maintain distal perfusion include the use of a downstream cannula or sewing on a side graft, but these techniques are cumbersome, time-consuming, and require additional equipment As a result, current practice is relying on the very small volume of blood that will flow around the cannula and collateral circulation to keep the leg viable, but by the time ischemia is clinically evident, irreversible cell damage may have already occurred The aim of this study is to evaluate the safety and efficacy of the novel bidirectional cannula (BiflowTM, LivaNova, Italy) with specific design to ensure stable distal perfusion compared to conventional cannula with downstream line in patients undergoing femoral arterial cannulation for CPB during MICS

Registry
clinicaltrials.gov
Start Date
March 1, 2020
End Date
June 15, 2020
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Serdar Günaydın

Professor

Ankara City Hospital Bilkent

Eligibility Criteria

Inclusion Criteria

  • Patient undergoing minimally invasvie aortic valve replacement 50-90 years of age

Exclusion Criteria

  • previous vascular surgery of the femoral artery, emergency cardiac surgery including type A aortic dissections, internal diameter of the common femoral artery less than 7.5 mm and where the clinician felt adequate flow rates and line pressures would not be achievable with a 19F cannula, because of the patient's weight and body surface area

Outcomes

Primary Outcomes

Vascular complications

Time Frame: one moth

infection, emboli, hematoma, bleeding

Study Sites (1)

Loading locations...

Similar Trials